• Home
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Jacinta Flattery O’Brien PhD
    • Jennifer Enmon PhD JD
    • Grant Shoebridge PhD
    • Kadri Elcoat
    • Kate Legge
    • Lesley White
    • Alex May
    • Christopher Coates
    • Jessica Chadbourne PhD
    • Joanne Grant
    • Emily Bristow
    • Brittany Deleon
    • Erni Othman
    • Amber Cross
  • News
    • Pearce IP Blog
    • BioBlast™
  • Blog
  • BioBlast™
  • Contact Us

ADQ acquires Pharmax Pharmaceuticals, invests in Biocon

by Bioblast Editor | Jan 7, 2021 | Biosimilars Deals 2020

ADQ announces it will acquire Pharmax Pharmaceuticals, as well as investing in a minority stake in Biocon Biologics.

Alvotech and Kamada enter biosimilar commercialisation agreement

by Bioblast Editor | Dec 2, 2019 | Biosimilars Deals 2019

Alvotech and Kamada announce agreement to commercialise six biosimilar products in Israel. The first product is expected to be launched in Israel in 2022.

Alvotech and STADA enter commercialisation agreement for biosimilars in EU

by Bioblast Editor | Nov 6, 2019 | Biosimilars Deals 2019

Alvotech and STADA announce agreement for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe. Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars,...

Biocon and Evotec enter strategic licensing agreement for biosimilar

by Bioblast Editor | Oct 14, 2019 | Biosimilars Deals 2019

Biocon and Evotec announce strategic licensing agreement for an early-stage biosimilar. Under this agreement, Biocon will take the asset through end-to-end development, IND filing, manufacturing and commercialisation and post-regulatory approval.

Biocon purchases R&D site from Pfizer

by Bioblast Editor | Sep 24, 2019 | Biosimilars Deals 2019

Biocon announces purchase of 60,000 square foot R&D site from Pfizer. The site in Chennai, India will house 250 scientists and is expected to be operational in a few months.
Page 1 of 512345»

SUBSCRIBE TO PEARCE IP

Sign up to our latest news

Receive our Pearce IP Blog and weekly BioBlast™ via email.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast™
  • Contact Us
  • Follow

Copyright © 2021 Pearce IP. All Rights Reserved.

Contact Us

Email: info@pearceIP.law
Tel: +61 (0) 2 9023 9988

For any general inquiries, please fill in the following contact form:

 





    Subscribe to our BioBlast™

    Fill in the form below to recieve our BioBlast™ Updates, Pearce IP Blog and other relevant industry updates.

     



      What emails do you want to receive?